Ziopharm Oncology (ZIOP) Announces Proposed Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ziopharm Oncology (ZIOP) Prices 27.826M Share Common Offering at $3.25/Sh
February 7, 2020 5:59 AM ESTZiopharm Oncology, Inc. (Nasdaq: ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase up to an additional 4,173,912... More
Pre-Open Stock Movers 2/5: (ABUS) (COTY) (QGEN) Higher (PLT) (KN) (SNAP) Lower (more...)
February 5, 2020 9:15 AM ESTPre-Open Stock Movers
Plantronics (NYSE: PLT) 30% LOWER; reported Q3 EPS of $0.30, $0.16 better than the analyst estimate of $0.14. Revenue for the quarter came in at $392 million versus the consensus estimate of $400.51 million. Plantronics sees Q4 2020 EPS of ($0.36)-$0.19, versus the consensus of $0.51. Plantronics sees Q4 2020 revenue of $354-394 million, versus the consensus of $441 million.
Ziopharm Oncology (ZIOP) Prices 27.83M Share Common Offering at $3.25/Sh
February 5, 2020 9:03 AM ESTZiopharm Oncology, Inc. (NASDAQ: ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to purchase up to an additional 4,173,912... More
